OncoMatch/Clinical Trials/NCT07450976
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Is NCT07450976 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies SHR-A1904 for for biliary tract cancer.
Treatment: SHR-A1904 for — This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC). Patients will treat with SHR-A1904 until unacceptable toxicity or disease progression.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: CLDN18 positive expression
CLDN18.2 positive expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic chemotherapy
Subjects who failed or intolerance after systemic chemotherapies
Cannot have received: anti-tumor treatment (chemotherapy, radiotherapy, immunotherapy, biotherapy, or other clinical research drugs)
Received anti-tumor treatment such as chemotherapy, radiotherapy, immunotherapy, biotherapy or other clinical research drugs within 4 weeks before the first administration
Lab requirements
Liver function
Child-Pugh liver function grade C excluded
Cardiac function
Severe heart disease within 6 months before first administration excluded
The main organ function is normal, in line with the program requirements; Child-Pugh liver function grade C excluded; severe heart disease within 6 months before first administration excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07450976 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-tumor treatment (chemotherapy, radiotherapy, immunotherapy, biotherapy, or other clinical research drugs) disqualifies patients from enrollment.
Does this trial require CLDN18?
Yes, CLDN18 positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages